Literature DB >> 26176283

Alopecia areata update.

Maria Hordinsky1, Ana Lucia Junqueira2.   

Abstract

There is neither a cure for alopecia areata (AA) nor any universally proven therapy that induces and sustains remission in patients afflicted with this autoimmune disease. AA is characterized as a nonscarring alopecia which affects children and adults. It can be relatively easy to treat when the disease is patchy and limited; but when children and adults present with long standing extensive scalp and body hair loss, successful management can be challenging. Of the treatment choices available, physicians and midlevel providers usually select a cost-effective treatment approach based on disease duration, disease activity, age of the patient, and disease extent. In this manuscript, the clinical presentation, epidemiology, pathophysiology, plus current and evolving treatments for AA will be reviewed. ©2015 Frontline Medical Communications.

Entities:  

Keywords:  alopecia areata; pathophysiology; treatment

Mesh:

Year:  2015        PMID: 26176283     DOI: 10.12788/j.sder.2015.0160

Source DB:  PubMed          Journal:  Semin Cutan Med Surg        ISSN: 1085-5629


  3 in total

1.  Fibroblast cell-based therapy prevents induction of alopecia areata in an experimental model.

Authors:  Reza B Jalili; Ruhangiz T Kilani; Yunyuan Li; Mohsen Khosravi-Maharlooie; Layla Nabai; Eddy Hsi Chun Wang; Kevin J McElwee; Aziz Ghahary
Journal:  Cell Transplant       Date:  2018-06-05       Impact factor: 4.064

2.  Consensus on the treatment of alopecia areata - Brazilian Society of Dermatology.

Authors:  Paulo Müller Ramos; Alessandra Anzai; Bruna Duque-Estrada; Daniel Fernandes Melo; Flavia Sternberg; Leopoldo Duailibe Nogueira Santos; Lorena Dourado Alves; Fabiane Mulinari-Brenner
Journal:  An Bras Dermatol       Date:  2020-10-08       Impact factor: 1.896

Review 3.  Evaluating the Therapeutic Potential of Ritlecitinib for the Treatment of Alopecia Areata.

Authors:  Hassiel Aurelio Ramírez-Marín; Antonella Tosti
Journal:  Drug Des Devel Ther       Date:  2022-02-17       Impact factor: 4.162

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.